Study of protein in blood to predict liver spread of colon cancer
Part of Cancer, Digestive system clinical trials.
This study looks at whether a substance in your blood (called PRDX1, found in tiny particles called exosomes) can help predict if colon cancer will spread to the liver after surgery. It may help doctors understand who needs more monitoring or treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 19 and 80 years old.
- You have been diagnosed with colon adenocarcinoma (a type of colon cancer).
- You have already had surgery to remove your colon cancer.
- You do not have serious liver disease, such as hepatitis or cirrhosis.
- You have not had other cancer treatments like chemotherapy or radiation before your surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a simple blood test can detect early signs of colorectal cancer coming back after surgery to remove cancer spread in the abdomen. It may help patients avoid unnecessary treatments and catch recurrence sooner.
This trial tests whether a special blood test that detects cancer DNA can help doctors decide if you need additional chemotherapy after colorectal cancer surgery. The goal is to personalize treatment based on your individual risk rather than giving chemotherapy to everyone.
This study looks at special tiny cell-signal particles (called exosomes) and related pathways to understand colorectal cancer. Your results from samples may help researchers learn how these signals relate to the disease after surgery.
This study looks at your tumor's genetic makeup and a blood test after surgery to better predict if colorectal cancer that spread to the liver might come back early. The goal is to personalize follow-up care and potentially guide additional treatments.
This study is testing whether a blood test that looks for tiny bits of tumor DNA (ctDNA methylation) can help monitor how well treatment is working in people with colorectal cancer that has spread. If you are getting radiation and chemotherapy (with or without an immunotherapy drug), this trial may help your doctor see if the treatment is working sooner.
This trial studies a blood test (called ctDNA) in people with colon cancer that has spread to the liver and is being removed with curative surgery. The goal is to see how the blood test can help with planning and improving treatment after surgery.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.